glp-1 drugs for parkinson's disease does not slow progression in phase 3 study GLP-1s are everywhere, but why?

How Quickly Will I Feel a Difference

The episode explores the science, clinical applications, and real-world considerations surrounding todays most discussed peptide therapies

We generated GS via photolytic homolysis of the S-N bond of S -nitrosoglutathione (GSNO) 30

A.LunardiG.DoimoM.TrevissonE.SalviatiL

Additionally, these agents suppress glucagon secretion, slow gastric emptying, and act on central appetite centers in the brain to increase satiety and reduce food intake

Neuronutrition interventions could help clinicians to provide personalized non-pharmocogical recommendations for patients with FM based on their symptoms and mechanisms of nutrient action